This promotional symposium session has been developed, organised and funded by Novo Nordisk. Novo Nordisk treatments may be discussed for the treatment of diabetes mellitus. Prescribing information can be accessed using the links below.
The Chronic Conditions webcast series and supporting materials was developed by the Chronic Conditions faculty in conjunction with OmniaMed Communications. Novo Nordisk has had no input into the agenda, speaker selection, presentations, or collateral content, with the exception of their promotional symposium session, for which they are fully responsible.
This promotional video presentation was originally broadcast on 27 May 2021.
Please note that the speakers are not able to answer questions from attendees watching the video on-demand.
At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.
Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.
Job code: UK21TSM00081 | Date of prep: May 2021